Melanoma Clinical Trials in New York

Showing 181-200 of 311 trials

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

NCT02334735

Vaccine adjuvants are compounds used to increase specific immune responses to antigens, but have minimal toxicity or lasting immune effects on their own. This study investigates the use of dendritic cells as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides compared to Montanide® in study subjects with melanoma in complete clinical remission.

Melanoma

Nina Bhardwaj36 participantsStarted Jul 2015

New York, New York, United States • New York, New York, United States

COMPLETEDPhase 1< 1 mile

A Study of PLX2853 in Advanced Malignancies.

NCT03297424

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Small Cell Lung CancerUveal MelanomaOvarian Clear Cell Carcinoma+5 more

Opna Bio LLC49 participantsStarted Sep 2017

Scottsdale, Arizona, United States • Miami, Florida, United States • New York, New York, United States +2 more locations

COMPLETEDNA< 1 mile

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

NCT00297895

Subjects must be diagnosed with melanoma. All subjects receive sentinel lymphadenectomy. If the subject is sentinel node positive and meets study requirements, the subject is randomized to receive either (1) completion lymphadenectomy (2) observation with nodal ultrasound. Subjects are then followed for 10 years.

Melanoma

Saint John's Cancer Institute1,939 participantsStarted Sep 2004

San Diego, California, United States • Santa Monica, California, United States • Colorado Springs, Colorado, United States +60 more locations

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Study of PLX2853 in Advanced Malignancies.

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma Trials in Other Cities

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

Safety Study of MGA271 in Refractory Cancer

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Other Conditions in New York